+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients



Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients



Infection Control and Hospital Epidemiology 28(9): 1054-1059



OBJECTIVE. Vancomycin-resistant enterococci (VRE) are a major cause of nosocomial infection. We sought to compare vancomycin-resistant (VR) Enterococcus faecalis bacteremia and VR Enterococcus faecium bacteremia in cancer patients with respect to risk factors, clinical presentation, microbiological characteristics, antimicrobial therapy, and outcomes.METHODS. We identified 210 cancer patients with VRE bacteremia who had been treated between January 1996 and December 2004; 16 of these 210 had VR E. faecalis bacteremia and were matched with 32 patients with VR E. faecium bacteremia and 32 control patients. A retrospective review of medical records was conducted.RESULTS. Logistic regression analysis showed that, compared with VR E. faecalis bacteremia, VR E. faecium bacteremia was associated with a worse clinical response to therapy (odds ratio [OR], 0.3 [95% confidence interval (CI), 0.07-0.98]; P = .046) and a higher overall mortality rate (OR, 8.3 [95% CI, 1.9-35.3]; P = .004), but the VRE-related mortality rate did not show a statistically significant difference (OR, 6.8 [95% CI, 0.7-61.8]; P = .09). Compared with control patients, patients with VR E. faecalis bacteremia were more likely to have received an aminoglycoside in the 30 days before the onset of bacteremia (OR, 5.8 [95% CI, 1.2-27.6]; P = .03), whereas patients with VR E. faecium bacteremia were more likely to have received a carbapenem in the 30 days before the onset of bacteremia (OR, 11.7 [95% CI, 3.6-38.6]; P < .001). In a multivariate model that compared patients with VR E. faecium bacteremia and control patients, predictors of mortality included acute renal failure on presentation (OR, 15.1 [95% CI, 2.3-99.2]; P = .004) and VR E. faecium bacteremia (OR, 11 [95% CI, 2.7-45.1]; P < .001). No difference in outcomes was found between patients with VR E. faecalis bacteremia and control patients.CONCLUSIONS. VR E. faecium bacteremia in cancer patients was associated with a poorer outcome than was VR E. faecalis bacteremia. Recent receipt of carbapenem therapy was an independent risk factor for VR E. faecium bacteremia, and recent receipt of aminoglycoside therapy was independent risk factor for E. faecalis bacteremia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 016587650

Download citation: RISBibTeXText

PMID: 17932826

DOI: 10.1086/519932


Related references

Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremia. Antimicrobial Agents and ChemoTherapy 56(5): 2452-2458, 2012

Risk factors for Enterococcus-associated mortality after bacteremia with Vancomycin-resistant Enterococcus faecium. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36: 236, 1996

Differences in Outcomes for Patients with Bacteremia Due to Vancomycin-Resistant Enterococcus faecium or Vancomycin-Susceptible E. faecium. Clinical Infectious Diseases 22(4): 663-670, 1996

Differences of outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clinical Infectious Diseases 22(4): 663-670, 1996

Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis. Journal of Microbiology, Immunology, and Infection 41(2): 124-129, 2008

Bacteremia with vancomycin resistant Enterococcus faecium and vancomycin sensitive Enterococcus faecium Comparison of epidemiology and clinical outcome. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 33: 275, 1993

Comparative evaluation of penicillin, ampicillin, and imipenem MICs and susceptibility breakpoints for vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. Journal of Clinical Microbiology 39(7): 2729-2731, 2001

Presence of virulence factors in Enterococcus faecalis and Enterococcus faecium susceptible and resistant to vancomycin. Memorias do Instituto Oswaldo Cruz 108(5): 590-595, 2013

Independent risk factors for the co-colonization of vancomycin-resistant Enterococcus faecalis and methicillin-resistant Staphylococcus aureus in the region most endemic for vancomycin-resistant e. 2013

New combinations of mutations in VanD-Type vancomycin-resistant Enterococcus faecium, Enterococcus faecalis, and Enterococcus avium strains. Antimicrobial Agents and ChemoTherapy 53(5): 1952-1963, 2009

Geographic region as a risk factor for clonality among nosocomial isolates of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis. Abstracts of the General Meeting of the American Society for Microbiology 98: 190, 1998

Relationship of the incidence of vancomycin-resistant Enterococcus faecium and vancomycin-sensitive Enterococcus faecium Evidence for enhanced pathogenicity due to vancomycin-resistance. Abstracts of the General Meeting of the American Society for Microbiology 95: 111, 1995

Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection. Clinical Infectious Diseases 20(5): 1126-1133, 1995

Treatment outcomes of vancomycin-resistant E faecium and vancomycin-resistant E faecalis compared with vancomycin -susceptible enterococcal bacteremia. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 643, 1999

Prevalence, outcome and risk factor associated with vancomycin-resistant Enterococcus faecalis and Enterococcus faecium at a Tertiary Care Hospital in Northern India. Indian Journal of Medical Microbiology 34(1): 38-45, 2016